The presentations underscore the company's research into sustained patient care for those with moderately to severely active Crohn's disease and ulcerative colitis. Long-term results from the COMMAND and U-ENDURE studies indicate that both therapies maintain efficacy over extended treatment periods. Notably, upadacitinib demonstrated clinical remission in up to 86.6% of Crohn's disease patients at week 144, while real-world evidence from the UPlift study showed a median time to first response of just 13 days.

Beyond established medications, AbbVie is introducing findings for the investigational dual-targeting therapy ABBV-466. Preliminary data from the Phase 2a TARGET-CD study suggest this novel approach may achieve endoscopic remission by simultaneously inhibiting inflammatory signaling and immune-cell trafficking. According to Sofie Berg, the therapeutic area head for immunology, these findings are vital for clinicians aiming to improve long-term outcomes in everyday practice. The company also reported that patients switching from tumor necrosis factor inhibitors to upadacitinib experienced fewer hospitalizations and surgeries, potentially signaling a shift in treatment patterns for complex IBD cases.